Ixtlan

Sinobiomed's Good News Raises Suspicion

500k is indeed a relatively small amount....however, there could be warrants attached for a larger aggregate amount..

additionally, professional relationships that accelera has might very well extend into the life science field both in china and in the u.s....

further, it would be possible that this is the first step of several that could put the company in an 'interesting' position - there are a handful of larger, listed companies that trade in the u.s. that produce and distribute generic drugs and partnering with a company that has some novel drugs in the pipeline is a great way to expand future growth drivers....this could include strategic investment, strategic partnership and/or m&a...

you make a very good point about the SFDA and the myriad ways in which they work...let's hope that sinobiomed is in the know and able to successfully navigate thru the balance of the clinical trials.